Reshaping the HIV treatment and prevention landscape

General Medicines portfolio resilient and highly profitable Broadly stable sales, 2021-26 (£m) Illustrative 2017 | Emerging markets General Medicines ex EMS 2021 2026 Primary care strategy and outlook - - Trelegy growing globally, resourced to win Investment concentrated on key brands - Significant growth driver in Emerging Markets Optimised for profitability, cash - Attractive margins fuel investment in growth drivers - Portfolio optimisation: reduced from >400 brands to ~200 since 2017, further simplification planned - Ongoing projects to improve COGS, supply chain gsk 40

View entire presentation